Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer
Sun Y.,Chinese Academy of Sciences |
Wang J.W.,Chinese Academy of Sciences |
Liu Y.Y.,Liaoning Provincial Cancer Hospital |
Yu Q.T.,Guangxi Medical University |
And 21 more authors.
Thoracic Cancer | Year: 2013
Background:: Phase II-III trials in patients with untreated and previously treated locally advanced or non-small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of platinum-based chemotherapy (NP regimen) with tolerable adverse effects. Methods: Four hundred and eighty six patients were randomized into two arms: study arm A: NP plus Endostar (n = 322; vinorelbine, cisplatin, Endostar), and study arm B: NP plus placebo (n = 164; vinorelbine, cisplatin, 0.9% sodium chloride). Patients were treated every third week for two to six cycles. Results:: Overall response rates were 35.4% in arm A and 19.5% in arm B (P = 0.0003). The median time to progression was 6.3 months for arm A and 3.6 months for B, respectively (P < 0.001). The clinical benefit rates were 73.3% in arm A and 64.0% in arm B (P = 0.035). Grade 3/4 neutropenia, anemia, and nausea/vomiting were 28.5%, 3.4%, and 8.0%, respectively, in Arm A compared with 28.2%, 3.0%, and 6.6%, respectively, in Arm B (P > 0.05). There were two treatment related deaths in arm A and one in arm B (P > 0.05). The median overall survival was longer in arm A than in arm B (P < 0.0001). Conclusion:: Long-term follow-up revealed that the addition of Endostar to an NP regimen can result in a significant clinical and survival benefit in advanced NSCLC patients, compared with NP alone. © 2013 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd.
Zhang Y.,Henan Provincial Cancer Hospital
Chinese Journal of Clinical Oncology | Year: 2010
Objective: To study the clinical significance of serum soluble E-selectin (sE-selectin) in diagnosis and treatment of gastric cancer. Methods: Serum E-selectin was detected with ELISA in 200 cases of gastric cancer, 45 cases of benign gastric diseases and 40 healthy controls. The changes in serum sE-selectin level of 140 patients with gastric cancer were analyzed before and after surgery, and the positive ratio of sE-selectin was compared with that of CEA, CA199 and CA724 in patients with gastric cancer. Results: The level of serum sE-selectin in patients with gastric cancer was 69.12±18.19 ng/mL, higher than that in those with benign diseases [(19.47±7.88)ng/mL] and healthy controls [(15.85±5.27)ng/mL]. The differences were significant (P<0.01). The level of serum sE-selectin was correlated with clinical stage and hepatic metastasis in gastric cancer patients, but was not correlated with focal location and histological grade (P>0.05). The positive rate of serum sE-selectin in cases with hepatic metastasis was higher than that in those without hepatic metastasis (P<0.01). The level of serum sE-selectin in patients with gastric cancer declined significantly at one month after surgery. The positive rate of serum sE-selectin in patients with gastric cancer was much higher than that of other digestive tumor markers (CEA, CA199, and CA724, P<0.01). Conclusion: sE-selectin may be a valuable marker for early diagnosis and prognosis of gastric cancer.
Zhu S.,Zhengzhou University |
Gong G.,Zhengzhou University |
Oremo J.A.,Zhengzhou University |
Zhen M.,Zhengzhou University |
And 3 more authors.
Information Technology Journal | Year: 2013
Analyzing Differential Expression Gene (DEG) and identifying candidate gene in prostate cancer cell lines that were resistant to docetaxel, which might be used for the purposes of screening targeted therapy. Gene expression pro?les of the tumors from docetaxel treated mice were performed using Agilent human whole genomic oligonucleotide microarrays. The microarray data were validated and the differential expression genes were analyzed using IPA software. The prostate cancer cell lines PCS and LNCaP were sensitive to docetaxel but VcaP and CWR22 were resistant to docetaxel cell lines. It indicated that some genes up-regulated or down-regulated in docetaxel resistant cell lines may be candidate genes for targeted therapy, after evaluating by Gene Expression Microarray and signal pathway. The significantiy up-regulated genes including Bcl-11 A, EPHA4 and CX3CL1 may be the potential candidates for further investigation in docetaxel-resistant tumor cells. © 2013 Asian Network for Scientific Information.
Zou B.,University of Sichuan |
Li T.,Sichuan Provincial Cancer Hospital |
Zhou Q.,Suining Center Hospital |
Ma D.,North Sichuan Medical College |
And 14 more authors.
Medicine (United States) | Year: 2016
To evaluate the treatment pattern and survival of patients receiving radical resection for primary small cell carcinoma of the esophagus (PSCCE). This retrospective study included 150 patients who received radical resection of PSCCE. Data were retrieved from 4 centers in Western China. Thirty-nine of 150 patients received postoperative chemo-radiotherapy, 62 received postoperative chemotherapy, and 49 received radical resection only. The median radiation dosage was 50 Gy. The chemotherapeutic regimen was platinum-based and lasted for 2 to 6 cycles (median, 3). Median disease-free survival (mDFS) and overall survival (mOS) were 12.0 and 18.3 months, respectively. Subgroup analysis revealed that postoperative therapy did not improve survival in limited stage I (LSI) disease, whereas postoperative chemotherapy improved survival in limited stage II (LSII) disease. Relative to chemotherapy alone, chemoradiotherapy did not improve survival in patients with completely resected LSII disease. A multivariate analysis indicated an association of no postoperative chemotherapy with shorter DFS (P = 0.050) and OS (P = 0.010). Higher lymph node stage and length of disease longer than 3 cm were poor prognostic factors for both DFS and OS. Adjuvant chemotherapy improves survival in PSCCE patients with completely resected LSII disease. Adjuvant treatment with postoperative chemotherapy alone or postoperative chemo-radiotherapy does not increase survival in completely resected LSI disease. © Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
Huang C.,Henan Provincial Cancer Hospital |
Yu W.,Henan Provincial Cancer Hospital |
Cui H.,Henan Provincial Cancer Hospital |
Wang Y.,Henan Provincial Cancer Hospital |
And 3 more authors.
Molecular Medicine Reports | Year: 2014
P2X7 is important in inflammation and tissue injury. The aim of the present study was to investigate the effect of P2X7 inhibition, using a specific inhibitor (A438079) to prevent the development of liver injury and fibrosis in a mouse model of liver fibrosis. The mouse liver fibrosis model was induced by carbon tetrachloride (CCl4). Mice received subcutaneous administration of vehicle (saline/olive oil), CCl4 or subcutaneous CCl4 and A438079. The pro-inflammatory and pro-fibrotic factors were determined by western blot analysis. The biochemistry, histopathology, collagen deposition and nuclear factor-κB (NF-κB) activity were also analyzed. Chronic CCl4 treatment resulted in liver injury and collagen accumulation. The expression levels of P2X7, pro-inflammatory and pro-fibrotic mediators, and the activity of NF-κB were markedly increased. Treatment with A438079 significantly inhibited CCl4-induced P2X7 expression, and attenuated CCl4-induced liver injury and the inflammatory response. P2X7 blockade also significantly reduced the formation of collagen in the liver and the expression of α-smooth muscle actin and transforming growth factor-β1. This study demonstrated that P2X7 inhibition attenuated liver injury and fibrosis in a mouse model. Thus, P2X7 is a potential novel therapeutic target for liver injury and fibrosis.